

AM-101305USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit:
)
Cooperstone et al) Examiner:
)
Appln. No. 10/767,824)
)
Filed: January 29, 2004)
)
For: METHOD OF TREATING HEPATIC)
FIBROSIS) April 29, 2004

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and a copy of the documents are enclosed herewith. This Information Disclosure Statement is submitted within three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

EXPRESS MAIL NO. EU531571284US

CUSTOMER NO. 38199

PTO/SB/08B (08-00)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB control number.

				k Reduction Act of 1995,	no pe	rsons are	required to respond to	a colle		plete if Know		ins a valid OMB control numb	er.
Substitute	e for for	n 1449	/РТО			Appl	ication Number		10/7	10/767,824			
INFORMATION DISCLOSURE						Filing Date J			January 29, 2004				\neg
STATEMENT BY APPLICANT						First Named Inventor C		Cooperstone et al		400 0 0 000	31		
(Use as many sheets as necessary)					Group Art Unit						APR 2 8 2004 IN		
						Exar	niner Name				-/3		
Sheet	Sheet 1 of 3					Atto	ney Docket Num	ber	AM-	101305USA		PAORUM	
			J	1		U.S. PA	ATENT DOCUMEN	TS					
Examiner Initials* Cite No.1						Publication Date MM-DD-YYYY			Name of Patentee or Applicant of Cited		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	•	'°. [Number-	Kind Code ^{2(if known)}		MM-DD-TTTT			Doo	tument			
	A		US-3,	929,992	1.	2-30-1	975	Se	hgal e	t al			
	В		US-3,	993,749	1	1-23-1	976	Se	hgal e	t al			
	C		US-4,	401,653	0	8-30-1	983	Ch	nee P.I	∃ng			
	D		US-4,	885,171	1.	2-5-19	89	Se	hgal e	t al			
	E		US-5,	078,999	0	01-07-1992 V			Warner et al				
	F		US-5,	080,899	0	01-14-1992		St	turm et al				
	G		US-5,	100,899	0	3-31-1	992	Si	Sir R. Calne				
	Н		US-5,	JS-5,362,718			11-08-1994		Skotnicki et al		-		\Box
	I		US-5,321,009 US-5,206,018			06-14-1994 04-27-1993		Ba	Baeder et al				
	J							Sehgal et al			, ,	\neg	
	K		US-5,	286,730	02-15-1		994	Ca	Caufield et al				
	L		US-5,286,731			02-15-1994		Caufield et al					
	М		US-5,288,711		0	02-22-1994		Mitchell et al					
	N		US-5,	387,589	0	2-07-1	995	Pr	rasad S. Kulkarni				
					F	DREIGN	PATENT DOCUM	ENTS	3				
Examiner Initials*	Cite No.1	Cour	Foreign Patent Document untry Code ³ - Number ⁴ -Kind Code ⁵		Foreign Patent Document Code ³ - Number ⁴ -Kind Code ⁵ (<i>if known</i>)		- Publication Date MM-DD-YYYY			Name of Patente or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ⁶
4	0	EP	05	0525960		1	03-20-1996			American Home Products			
										Corporation			
1	P	PC	r + w	O 03/077915	+	1	09-25-2003			Wyeth	-		
<u></u>	Q	PC		O 01/97809	A	2	12-27-2001			American			
~	`	- 0.							•	Home Prod	ucts		
										Corporation	1		
Examiner Signature								Date Cons	idered				
* FXAMINE	FR · Initi:	al if ref	erence c	onsidered whether o	r not	citation	is in conformance v	with M	IPFP 609	Draw line thr	ough c	itation if not in conforma	nce

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place

a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

			<u> </u>	Complete if Known					
Substitute	e for form 1	1449/Р1О		Application Number	10/767,824	OIPE			
INF	ORMA	TION	DISCLOSURE	Filing Date	January 29, 2004	/ 2			
			APPR 2 9 2006						
(4	Use as ma	ny sheets	as necessary)	Group Art Unit		E E	Γ		
				Examiner Name		CHY. S. S.			
Sheet	3	of	3	Attorney Docket Number	AM-101305USA	WORLD)			

Cite No.1	the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse							
W	STARUCH ET AL, FK506 and Rapamycin Inhibit Murine T Cell Activation Through Different Mechanisms, The FASEB Journal, Vol. 3, No. 3 3411, (1989)							
X	SEHGAL ET AL, Rapamycin (AY-22, 989), A New Antifungal Antibiotic, II. Fermentation, Isolation and Characterization, The Journal of Antibiotics, Vol. XXVIII No. 10, pp. 727-732 (October 1975)							
Y	VEZINA ET AL, Rapamycin (AY-22,989), A New Antifungal Antibiotic I. Taxonomy of the Producing Streptomycete and Isolation of the Active Principle, The Journal of Antibiotics, Vol. XXVIII No. 10, pp. 721-726 (October 1975)							
Z	BAKER ET AL, Rapamycin (AY-22,989), A New Antifungal Antibiotic, III. In Vitro and In Vivo Evaluation, The Journal of Antibiotics, Vol. XXXI, No. 6, pp. 539-545, (June 1978)							
AA	MARTEL ET AL, Inhibition of the Immune Response by Rapamycin, a New Antifungal Antibiotic, Can. J. Physiol. Pharmacol. Vol.55, pp. 48-51 (1977)							
BB	DUMONT ET AL, Rapamycin Blocks the Immunosuppressive Effect of FK506 But Not That of Cyclosporin A, FASEB JOURNAL, 5256, Vol. 3, No. 4, (1989)							
CC	R. Y. CALNE ET AL, Prolonged Survival of Pig Orthotopic Heart Grafts Treated with Cyclosporin A, Lancet, pp. 1183-1185, (June 3, 1978)							
	No.1 W X Y Z AA BB	the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published W STARUCH ET AL, FK506 and Rapamycin Inhibit Murine T Cell Activation Through Different Mechanisms, The FASEB Journal, Vol. 3, No. 3 3411, (1989) X SEHGAL ET AL, Rapamycin (AY-22, 989), A New Antifungal Antibiotic, II. Fermentation, Isolation and Characterization, The Journal of Antibiotics, Vol. XXVIII No. 10, pp. 727-732 (October 1975) Y VEZINA ET AL, Rapamycin (AY-22,989), A New Antifungal Antibiotic I. Taxonomy of the Producing Streptomycete and Isolation of the Active Principle, The Journal of Antibiotics, Vol. XXVIII No. 10, pp. 721-726 (October 1975) Z BAKER ET AL, Rapamycin (AY-22,989), A New Antifungal Antibiotic, III. In Vitro and In Vivo Evaluation, The Journal of Antibiotics, Vol. XXXI, No. 6, pp. 539-545, (June 1978) AA MARTEL ET AL, Inhibition of the Immune Response by Rapamycin, a New Antifungal Antibiotic, Can. J. Physiol. Pharmacol. Vol.55, pp. 48-51 (1977) BB DUMONT ET AL, Rapamycin Blocks the Immunosuppressive Effect of FK506 But Not That of Cyclosporin A, FASEB JOURNAL, 5256, Vol. 3, No. 4, (1989) CC R. Y. CALNE ET AL, Prolonged Survival of Pig Orthotopic Heart Grafts Treated						

Examiner	Date	
Signature	Considered	
O.B.Intara		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-00)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute f	for form	1440/	PTO.							lete if Know	'n	TPE	
Substitute for form 1449/PTO					Application Number		10/767,824						
INFORMATION DISCLOSURE						Filing	Date		Januar	ry 29, 2004	7	0 2004	
STAT	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor Group Art Unit			Cooperstone et al			APR 2 9 2004 2			
(Us								$-\epsilon$	3, 8				
						Exan	niner Name					TO TO ADELLE	
Sheet	Sheet 2 of 3					Attor	ney Docket Numb	er	AM-1	01305USA			
			<u> </u>	1		L	TENT DOCUMENT		1		-		
Examiner Initials*	Cit No		Do	cument Number			lication Date M-DD-YYYY	N	Applicant	ratentee or t of Cited		es, Columns, Lines, Whe evant Passages or Releva Figures Appear	
				Kind Code ^{2(if known)}	<u> </u>								
	R			496,832	1	-05-1		_	•	nstrong			
	S			516,781	<u> </u>	-14-1			orris et				
	T			561,138		-01-1			<u> </u>	nstrong			
<u></u>	U			277,983		-21-2			aw et a				
	V		US-6,	670,355	12	-30-2	003	Az	zrolan e	t al			
					<u> </u>								
				· · · · · · · · · · · · · · · · · · ·									
					1								
					1								
<u>-</u>													
		<u> </u>			FO	REIGN	PATENT DOCUMI	ENTS	3				
Examiner Initials*	Cite No.1	Foreign Patent Document			Publication Date					of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	76	
		count	ry Code	³ - Number ⁴ -Kind Code	:"(if kn	own)				Cited Docum		Appear	\square
								Dete		- · · · · · · · · · · · · · · · · · · ·			<u> </u>
Examiner Signature								Date Consi	idered				

document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231.

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place

REMARKS

Listed below are previously filed, co-pending, related U.S. patent and foreign applications. These applications and the present application are commonly owned:

Copies of the applications and claims are enclosed.

- U.S. Patent Application No. 10/313,217, filed December 6, 2002, U.S. Patent No. 6,670,355, issued on December 30, 2003
 U.S. Patent Continuation Application No. 10/696,256, filed October 29, 2003
 (International Application No. WO 01/97809, published December 27, 2001)
- (2) U.S. Patent Application No. 10/626,943, filed July 25, 2003
- (3) U. S. Patent Application No. 10/384,808, filed March 10, 2003 (International Application No. WO 03/077915, published September 25, 2003)
- (4) U.S. Patent Application No. 10/663,506 filed September 15, 2003

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON Attorneys for Applicant

Cathy A/Kodroff

Registration No. 33,980

Spring House Corporate Center

Box 457

Spring House, PA 19477 Phone: (215) 540-9200

Fax: (215) 540-5818

04-30-04

		Application Number	10/767,824				
		Filing Date	April 29, 2004				
TRANSMITTAL FORM		First Named Inventor	Cooperstone et al				
FORIVI		Group Art Unit					
(to be used for all correspondence after initial	filing)	Examiner Name					
otal Number of Pages in this Submission	6	Attorney Docket Number	AM-101305USA				
	ENCLOS	SURES (check all that	t apply)				
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application	G Addre	□ Drawing(s) □ After Allowance Coto Group □ Licensing-related Papers □ Appeal Communic of Appeals and Interest of Appeals and Interest of Appeals and Interest of Appeal Notice, Brief, R □ Power of Attorney, Revocation Change of Correspondence Address □ Proprietary Information □ Terminal Disclaimer □ Other Enclosure(stidentify below): □ Request for Refund 33-references Remarks					
Response to Missing Parts under 37 CFR 1.52 or 1.53							
	TURE O	F APPLICANT, ATTORNE	Y, OR AGENT				
Firm Howson and or ndividual Name Cathy A. Kod							
Signature Cathy a Kodio 77							
Date April 29, 2004	1	UU					
	ERTIFIC	CATE OF TRANSMISSION/	MAILING				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

Date

If you need assistance in completing the form, call 1 -800-PTO-9199 (1-800-786-9199) and select option 2.

Typed or printed name

Signature